Ben Haddou Tanila, Béni Szabolcs, Hosztafi Sándor, Malfacini Davide, Calo Girolamo, Schmidhammer Helmut, Spetea Mariana
Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences, University of Innsbruck, Innsbruck, Austria.
Department of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary.
PLoS One. 2014 Jun 11;9(6):e99231. doi: 10.1371/journal.pone.0099231. eCollection 2014.
Morphine and structurally related derivatives are highly effective analgesics, and the mainstay in the medical management of moderate to severe pain. Pharmacological actions of opioid analgesics are primarily mediated through agonism at the µ opioid peptide (MOP) receptor, a G protein-coupled receptor. Position 17 in morphine has been one of the most manipulated sites on the scaffold and intensive research has focused on replacements of the 17-methyl group with other substituents. Structural variations at the N-17 of the morphinan skeleton led to a diversity of molecules appraised as valuable and potential therapeutics and important research probes. Discovery of therapeutically useful morphine-like drugs has also targeted the C-6 hydroxyl group, with oxymorphone as one of the clinically relevant opioid analgesics, where a carbonyl instead of a hydroxyl group is present at position 6. Herein, we describe the effect of N-substituent variation in morphine and oxymorphone on in vitro and in vivo biological properties and the emerging structure-activity relationships. We show that the presence of a N-phenethyl group in position 17 is highly favorable in terms of improved affinity and selectivity at the MOP receptor, potent agonism and antinociceptive efficacy. The N-phenethyl derivatives of morphine and oxymorphone were very potent in stimulating G protein coupling and intracellular calcium release through the MOP receptor. In vivo, they were highly effective against acute thermal nociception in mice with marked increased antinociceptive potency compared to the lead molecules. It was also demonstrated that a carbonyl group at position 6 is preferable to a hydroxyl function in these N-phenethyl derivatives, enhancing MOP receptor affinity and agonist potency in vitro and in vivo. These results expand the understanding of the impact of different moieties at the morphinan nitrogen on ligand-receptor interaction, molecular mode of action and signaling, and may be instrumental to the development of new opioid therapeutics.
吗啡及其结构相关衍生物是高效镇痛药,是中重度疼痛医学管理的主要药物。阿片类镇痛药的药理作用主要通过作用于μ阿片肽(MOP)受体来介导,该受体是一种G蛋白偶联受体。吗啡结构中的17位一直是该骨架上被修饰最多的位点之一,大量研究集中于用其他取代基取代17位的甲基。吗啡喃骨架N-17位的结构变化产生了多种被评估为有价值的潜在治疗药物和重要研究探针的分子。治疗用类吗啡药物的发现也针对C-6羟基,羟吗啡酮是临床相关的阿片类镇痛药之一,其6位是羰基而非羟基。在此,我们描述了吗啡和羟吗啡酮中N-取代基变化对体外和体内生物学特性的影响以及新出现的构效关系。我们发现,17位存在N-苯乙基在提高对MOP受体的亲和力和选择性、强效激动作用和镇痛效力方面非常有利。吗啡和羟吗啡酮的N-苯乙基衍生物在通过MOP受体刺激G蛋白偶联和细胞内钙释放方面非常有效。在体内,它们对小鼠急性热痛觉有高效作用,与先导分子相比,镇痛效力显著增强。还证明,在这些N-苯乙基衍生物中,6位的羰基比羟基更可取,可增强体外和体内的MOP受体亲和力和激动剂效力。这些结果扩展了对吗啡喃氮上不同基团对配体-受体相互作用、分子作用模式和信号传导影响的理解,可能有助于开发新的阿片类治疗药物。